OM:SOBIBiotechs
What Swedish Orphan Biovitrum (OM:SOBI)’s EU Approval of Tryngolza for FCS Means for Shareholders
Earlier this week, Sobi and Ionis Pharmaceuticals announced the European Union approval of Tryngolza (olezarsen) as an adjunct to diet for adult patients with genetically confirmed familial chylomicronemia syndrome (FCS), based on positive Phase 3 results showing sustained reductions in triglyceride levels and clinically meaningful lower acute pancreatitis rates.
This approval marks a significant advance in FCS treatment options in Europe, and grants Sobi exclusive commercialization rights...